Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis

British Journal of Dermatology

Volumn 176, Issue 3, 2017, Pages 752-758

  Reich, K ^a   Blauvelt, A ^b   Armstrong, A ^c   Langley, R G ^d   Fox, T ^e   Huang, J ^e   Papavassilis, C ^e   Liang, E ^e   Lloyd, P ^e   Bruin, G ^e  

^a SCIderm Clinical Research and Dermatologikum   (Germany)

^b OREGON MEDICAL RESEARCH CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d DALHOUSIE UNIVERSITY   (Canada)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; SECUKINUMAB; DERMATOLOGICAL AGENT; IL17A PROTEIN, HUMAN; INTERLEUKIN 17; MONOCLONAL ANTIBODY;

ARTICLE; DERMATITIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS VULGARIS; STEADY STATE; TREATMENT DURATION; URTICARIA; FOLLOW UP; IMMUNOLOGY; METABOLISM; PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CLINICAL TRIALS, PHASE III AS TOPIC; DERMATOLOGIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-17; PSORIASIS; TREATMENT OUTCOME;

EID: 85005992410     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.14965     Document Type: Article

References (34)

1. Parisi R, Symmons DP, Griffiths CE et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133:377–85.
2. Tsai TF, Wang TS, Hung ST et al. Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. J Dermatol Sci 2011; 63:40–6.
3. de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004; 9:140–7.
4. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370:263–71.
5. Johansen C, Usher PA, Kjellerup RB et al. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol 2009; 160:319–24.
6. Lin AM, Rubin CJ, Khandpur R et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011; 187:490–500.
7. Lowes MA, Kikuchi T, Fuentes-Duculan J et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128:1207–11.
8. Martin DA, Towne JE, Kricorian G et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol 2013; 133:17–26.
9. + T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines. J Leukoc Biol 2009; 86:435–43.
10. Res PC, Piskin G, de Boer OJ et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS ONE 2010; 5:e14108.
11. Blauvelt A, Prinz JC, Gottlieb AB et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol 2015; 172:484–93.
12. Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 2014; 371:326–38.
13. Mrowietz U, Leonardi C, Girolomoni G et al. Secukinumab ‘fixed-interval’ vs. ‘retreatment-as-needed’ regimen for moderate-to-severe plaque psoriasis: a study comparing secukinumab use in long-term psoriasis maintenance therapy (SCULPTURE). Presented at the 22nd Congress of the European Academy of Dermatology and Venereology, 2–6 October 2013, Istanbul, Turkey; presentation FC01.5.
14. Paul C, Lacour JP, Tedremets L et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol 2015; 29:1082–90.
15. Thaçi D, Humeniuk J, Frambach Y et al. Secukinumab in moderate-to-severe plaque psoriasis: results from the Secukinumab Trial Analyzing the potential of intravenous administration To Upgrade the REsponse in psoriasis (STATURE). Presented at the 22nd Congress of the European Academy of Dermatology and Venereology, 2–6 October 2013, Istanbul, Turkey; poster P1505.
16. De Groot A, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol 2007; 28:482–90.
17. De Simone C, Amerio P, Amoruso G et al. Immunogenicity of anti-TNF-α therapy in psoriasis: a clinical issue? Expert Opin Biol Ther 2013; 13:1673–82.
18. Descotes J. Immunotoxicity of monoclonal antibodies. MAbs 2009; 1:104–11.
19. Leach MW, Rottman JB, Hock MB et al. Immunogenicity; hypersensitivity of biologics. Toxicol Pathol 2014; 42:293–300.
20. Purcell RT, Lockey RF. Immunologic responses to therapeutic biologic agents. J Investig Allergol Clin Immunol 2008; 18:335–42.
21. Bito T, Nishikawa R, Hatakeyama M et al. Influence of neutralizing antibodies to adalimumab and infliximab in the treatment of psoriasis. Br J Dermatol 2014; 170:922–9.
22. Carrascosa JM. Immunogenicity in biologic therapy: implications for dermatology. Actas Dermosifiliogr 2013; 104:471–9.
23. Hsu L, Snodgrass BT, Armstrong AW. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol 2014; 170:261–73.
24. Jullien D, Prinz JC, Nestle FO. Immunogenicity of biotherapy used in psoriasis: the science behind the scenes. J Invest Dermatol 2015; 135:31–8.
25. Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK; PD and efficacy. AAPS J 2012; 14:296–302.
26. Schouwenburg P, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013; 9:164–72.
27. Tovey M, Lalleman C. Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther Adv Drug Saf 2011; 2:113–28.
28. Klein U, Liang E, Vogel B et al. Immunogenicity of the anti-IL-17A antibody secukinumab in healthy subjects and patients. J Invest Dermatol 2013; 133(Suppl. 1):S172.
29. Langley RG, Feldman SR, Nyirady J et al. The 5-point Investigator's Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat 2015; 26:23–31.
30. U.S. Department of Health and Human Services. Assay development and validation for immunogenicity testing of therapeutic protein products. Available at: http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm192750.pdf (last accessed 13 September 2016).
31. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2010; 2:256–65.
32. Karle A, Spindeldreher S, Kolbinger F. Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity. MAbs 2016; 8:536–50.
33. Menter A, Feldman SR, Weinstein GD et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56:31e.1−15.
34. Reich K, Wozel G, Zheng H et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). Br J Dermatol 2013; 168:1325–34.